Cognetivity Neurosciences (Cognetivity Neurosciences) Debt-to-Equity : -0.18 (As of Oct. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Cognetivity Neurosciences Debt-to-Equity?

Cognetivity Neurosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2023 was $1.00 Mil. Cognetivity Neurosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2023 was $1.00 Mil. Cognetivity Neurosciences's Total Stockholders Equity for the quarter that ended in Oct. 2023 was $-11.08 Mil. Cognetivity Neurosciences's debt to equity for the quarter that ended in Oct. 2023 was -0.18.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cognetivity Neurosciences's Debt-to-Equity or its related term are showing as below:

CGNSF' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.52 Med: -0.26 Max: 3.6
Current: -0.18

During the past 7 years, the highest Debt-to-Equity Ratio of Cognetivity Neurosciences was 3.60. The lowest was -1.52. And the median was -0.26.

CGNSF's Debt-to-Equity is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 0.48 vs CGNSF: -0.18

Cognetivity Neurosciences Debt-to-Equity Historical Data

The historical data trend for Cognetivity Neurosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cognetivity Neurosciences Debt-to-Equity Chart

Cognetivity Neurosciences Annual Data

Trend

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Debt-to-Equity

Get a 7-Day Free Trial

-1.17

0.36

-0.23

-0.13

Cognetivity Neurosciences Quarterly Data
	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23
Debt-to-Equity	Get a 7-Day Free Trial															-0.21	-0.13	-0.12	-0.10	-0.18

Competitive Comparison of Cognetivity Neurosciences's Debt-to-Equity

For the Health Information Services subindustry, Cognetivity Neurosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cognetivity Neurosciences's Debt-to-Equity Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cognetivity Neurosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cognetivity Neurosciences's Debt-to-Equity falls into.

Cognetivity Neurosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cognetivity Neurosciences's Debt to Equity Ratio for the fiscal year that ended in Jan. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.962	+	0)	/	-7.368
	=	-0.13

Cognetivity Neurosciences's Debt to Equity Ratio for the quarter that ended in Oct. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.998	+	0.998)	/	-11.082
	=	-0.18

Cognetivity Neurosciences (OTCPK:CGNSF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cognetivity Neurosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cognetivity Neurosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cognetivity Neurosciences (Cognetivity Neurosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cognetivity Neurosciences Ltd (OTCPK:CGNSF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

1UB:Germany CGN:Canada

Address

800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6

Website

https://www.cognetivity.com

Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.

Cognetivity Neurosciences (Cognetivity Neurosciences) Headlines

From GuruFocus

The Most Innovative Healthcare AI Developments of 2019

By ACCESSWIRE AccessWire • 04-12-2019

Three Companies Using AI and Innovation to Lead Healthcare Sector

By ACCESSWIRE AccessWire • 04-12-2019